ImmuneBridge develops a cell therapy screening and manufacturing platform that combines machine-learning-enabled donor selection with a proprietary small molecule that preserves stem-cell pluripotency through repeated replications. This approach enables differentiation into T cells, NK cells, macrophages, or neutrophils and can produce thousands of high-quality doses from a single donor versus the industry standard of tens of doses. The company is shifting to a "picks and shovels" model by licensing its platform to external co-development partners, from startups to large pharma, and is already working with over a dozen collaborators. Following its recent financing, ImmuneBridge promoted Dr. Nina Horowitz to CEO and appointed Dr. Rui Tostoes as CTO to lead the scale-up of manufacturing. Financially, the company raised $7.7M in a second seed round led by NFX, bringing total seed funding to nearly $20M. ImmuneBridge aims to advance initial human trials in 2028 and bring 10 therapies to the clinic within the next decade.

Total raised

$20M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2026